Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024 [Yahoo! Finance]
NeutralReport
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024 [Yahoo! Finance]
Galapagos NV (NASDAQ: GLPG) had its "underperform" rating re-affirmed by analysts at Bank of America Co.. They now have a $31.00 price target on the stock, down previously from $41.00.
LowReport
Galapagos NV (NASDAQ: GLPG) had its "underperform" rating re-affirmed by analysts at Bank of America Co.. They now have a $31.00 price target on the stock, down previously from $41.00.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: